Thieler Law Corp advises investors with losses exceeding $100,000 of the December 23, 2019 lead plaintiff deadline in a class action lawsuit filed against Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) (“Zynerba” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Zynerba Pharmaceuticals Inc securities between March 11, 2019 and September 17, 2019, have until December 23, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Zynerba Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and as a result, Zynerba’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On September 18, 2019, the Company issued a press release announcing results from its open-label Phase 2 BELIEVE 1 clinical trial evaluating topical gel Zygel (ZYN002) in children and adolescents with developmental and epileptic encephalopathies.  According to the Company, Zygel was well-tolerated, it also disclosed that the rate of treatment-emerged adverse events was 96% and that “two [serious adverse events] (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment.”

Following this news, NASDAQ: ZYNE fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.

If you were negatively impacted by your investment in Zynerba Pharmaceuticals Inc securities between March 11, 2019 and September 17, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185